Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 19 Aug 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 19 Aug 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
- 19 Jan 2019 Results assessing the safety and antitumor activity of durvalumab in pateints with MSI-H tumors , in two ongoing studies (NCT01693562 and NCT02227667) presented at the 2019 Gastrointestinal Cancers Symposium